Tremfya
Named-patient access overview. Tremfya is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Tremfya (guselkumab) is an interleukin-23 (IL-23) inhibitor monoclonal antibody developed by Janssen Biotech, part of Johnson and Johnson. The US Food and Drug Administration first approved Tremfya in July 2017 for moderate-to-severe plaque psoriasis in adults, with subsequent approvals for active psoriatic arthritis (2020), moderately to severely active ulcerative colitis (2024), and moderately to severely active Crohn disease (2025).
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Tremfya
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Tremfya is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Tremfya in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Tremfya
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.